Journal
ONCOTARGET
Volume 7, Issue 3, Pages 2284-2296Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.6198
Keywords
hematological malignancies; EZH2; Polycomb complex; therapeutic target
Categories
Funding
- Languedoc Roussillon CRLR [R14026FF]
- Fondation de France [201400047510]
- ITMO Cancer (MMTT)
- French Labex EpiGenMed fellowship
Ask authors/readers for more resources
Enhancer of zeste homolog 2 (EZH2), the catalytic subunit of the Polycomb repressive complex 2, inhibits gene expression through methylation on lysine 27 of histone H3. EZH2 regulates normal hematopoietic stem cell self-renewal and differentiation. EZH2 also controls normal B cell differentiation. EZH2 deregulation has been described in many cancer types including hematological malignancies. Specific small molecules have been recently developed to exploit the oncogenic addiction of tumor cells to EZH2. Their therapeutic potential is currently under evaluation. This review summarizes the roles of EZH2 in normal and pathologic hematological processes and recent advances in the development of EZH2 inhibitors for the personalized treatment of patients with hematological malignancies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available